{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:10:08Z","timestamp":1784182208766,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cjco.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:11:57Z","timestamp":1773335517000},"page":"861-867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sociodemographic Characteristics Associated with PCSK9 Inhibitor Use in Individuals with Possible Familial Hypercholesterolemia in Alberta: A Cohort Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Samuel E.","family":"Fineblit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-3630","authenticated-orcid":false,"given":"David J.T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"176","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.03.002_bib2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.03.002_bib3","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.3390\/jcm10173828","article-title":"Trends in PCSK9 inhibitor prescriptions before and after the price reduction in patients with atherosclerotic cardiovascular disease","volume":"10","author":"Smith","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjco.2026.03.002_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005404","article-title":"Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes","volume":"12","author":"Myers","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/CIRCOUTCOMES.120.007237","article-title":"Predictors of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease","volume":"14","author":"Blumenthal","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2026.03.002_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2021.04.034","article-title":"Perceptions and barriers on the use of proprotein subtilisin\/kexin type 9 inhibitors in heterozygous familial hypercholesterolemia (from a survey of primary care physicians and cardiologists)","volume":"152","author":"Wong","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2026.03.002_bib7","first-page":"E618","article-title":"Income-related disparities in private prescription drug coverage in Canada","volume":"7","author":"Bolotova","year":"2019","journal-title":"Can Med Assoc J Open"},{"key":"10.1016\/j.cjco.2026.03.002_bib8","first-page":"3","article-title":"Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease","volume":"27","author":"Hennessy","year":"2016","journal-title":"Health Rep"},{"key":"10.1016\/j.cjco.2026.03.002_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healthpol.2019.12.007","article-title":"Socioeconomic differences in prescription drug supplemental coverage in Canada: a repeated cross-sectional study","author":"Guo","year":"2020","journal-title":"Health Policy"},{"key":"10.1016\/j.cjco.2026.03.002_bib10","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","article-title":"Full coverage for preventive medications after myocardial infarction","volume":"365","author":"Choudhry","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2147\/PPA.S170417","article-title":"Cost-related nonadherence to prescription medications in Canada: a scoping review","volume":"12","author":"Gupta","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.cjco.2026.03.002_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2369-10-30","article-title":"Overview of the Alberta Kidney Disease Network","volume":"10","author":"Hemmelgarn","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cjco.2026.03.002_bib13","first-page":"4255","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.03.002_bib14","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.03.002_bib15","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.03.002_bib16","first-page":"104","article-title":"A deprivation index for health and welfare planning in Quebec","volume":"21","author":"Pampalon","year":"2000","journal-title":"Chronic Dis Can"},{"key":"10.1016\/j.cjco.2026.03.002_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.24095\/hpcdp.29.4.05","article-title":"A deprivation index for health planning in Canada","volume":"29","author":"Pampalon","year":"2009","journal-title":"Chronic Dis Can"},{"key":"10.1016\/j.cjco.2026.03.002_bib18","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/BF03403824","volume":"103","author":"Pampalon","year":"2012","journal-title":"Can J Public Health"},{"key":"10.1016\/j.cjco.2026.03.002_bib19","author":"Gamache"},{"key":"10.1016\/j.cjco.2026.03.002_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-006809","article-title":"Regional and socioeconomic disparities in cardiovascular disease in Canada during 2005\u20132016: evidence from repeated nationwide cross-sectional surveys","volume":"6","author":"Dai","year":"2021","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.cjco.2026.03.002_bib22","author":"Johnston"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:37Z","timestamp":1784180257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X26000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589790X26000922"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2026.03.002","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sociodemographic Characteristics Associated with PCSK9 Inhibitor Use in Individuals with Possible Familial Hypercholesterolemia in Alberta: A Cohort Study","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}